Alexion Pharmaceuticals, Inc. (ALXN) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Tanker struck by projectile in Strait of Hormuz
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- AppLovin shares fall after court denies request against Unity
Alexion Pharma (ALXN) MAA for Asfotase Alfa Apprved by EMA
July 24, 2014 6:24 AM EDTAlexion Pharma (Nasdaq: ALXN) announced that the Marketing Authorization Application (MAA) for asfotase alfa, an investigational, first-in-class targeted enzyme replacement therapy for the treatment of hypophosphatasia (HPP), has been validated and granted accelerated assessment by the European Medicines Agency (EMA). The... More
